Osuga Y, et al. - Researchers investigated whether dienogest (DNG), a progestational 19-norsteroid, is efficacious and safe in treating patients with primary and secondary dysmenorrhea via conducting phase 3, randomized, double-blind, multicenter, placebo-controlled study at clinical study sites in Japan. They randomly assigned 94 women with dysmenorrhea to receive either DNG (1 mg/day, orally) or placebo for 12 weeks; treatment for anemia was provided to patients before randomization in cases of complicated anemia. Findings revealed the superiority of the DNG group to the placebo group with respect to the change from baseline in the dysmenorrhea score at week 12 of treatment in patients with dysmenorrhea. DNG at 1 mg/day resulted in relief in pain and was well tolerated in both primary and secondary dysmenorrhea.